Formulation, Development of a Transdermal Self-Microemulsifying Drug Delivery System of Dasatinib

Keywords

Abstract

References

1. [1]1. Homayun B, Lin X, Choi H-J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129.
2. [2]2. Shreya A, Raut SY, Managuli RS, Udupa N, Mutalik S. Active targeting of drugs and bioactive molecules via oral administration by ligand-conjugated lipidic nanocarriers: recent advances. AAPS PharmSciTech. 2018;20(1):15.
3. [3]3. Wadhwa J, Nair A, Kumria R. Self-emulsifying therapeutic system: a potential approach for delivery of lipophilic drugs. Brazilian J Pharmaceutical Sciences. 2011;47:447–65.
4. [4]4. 4Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’drug delivery systems. European journal of pharmaceutical sciences. 2000;11:S93–S8.
5. [5]5. Cohen P. Protein kinases—the major drug targets of the twenty-first century? Nature reviews Drug discovery. 2002;1(4):309–15.
6. [6]6. Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nature reviews drug discovery. 2021;20(7):551–69.
7. [7]7. Paul TR, Uppin SG, Uppin MS, Jacob RT, Rao DR, Rajappa SJ. Evaluation of cytopenias occurring in imatinib treated chronic myeloid leukemia (CML) patients. Indian Journal of Hematology and Blood Transfusion. 2010;26(2):56–61.
8. [8]8. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature medicine. 2006;12(8):908–16.
9. [9]9. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clinical Oncology. 2008;26(20):3358–63.
10. [10]10. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D-W, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology. 2010;28(3):424–30.
11. [11]11. Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer treatment reviews. 2015;41(5):412–22.
12. [12]12. Abbas R, Hsyu P-H. Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clinical pharmacokinetics. 2016;55(10):1191–204.
13. [13]13. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research. 2008;14(12):3881–8.
14. [14]14. van Erp NP, Gelderblom H, Guchelaar H-J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer treatment reviews. 2009;35(8):692–706.
15. [15]15. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer chemotherapy and pharmacology. 2008;61(3):365–76.
16. [16]16. Vaidhyanathan S, Wang X, Crison J, Varia S, Gao JZ, Saxena A, et al. Bioequivalence comparison of pediatric dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling. J Pharmaceutical Sciences. 2019;108(1):741–9.
17. [17]17. National Center for Biotechnology Information. Dasatinib | C22H26ClN7O2S | CID 3062316 - PubChem - NIH Bethesda, Maryland, USA: National Center for Biotechnology Information; 2020 [
18. [18]18. AMITAY‐LAISH I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatologic therapy. 2011;24(4):386–95.
19. [19]19. Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Current hematologic malignancy reports. 2016;11(2):71–9.
20. [20]20. Korashy HM, Rahman AM, Kassem MG. Dasatinib. Profiles of Drug Substances, Excipients and Related Methodology. 2014;39:205–37.
21. [21]21. Pattewar S, Kasture S, Pande V, Patil D, Sharma S. Development and Optimization of Piroxicam-loaded Solid Self-micro emulsifying Drug Delivery System. Indian J Pharm Sci. 2018;80(2):350–8.
22. [22]22. Rao MR, Munjapara GS, Khole IA. Preparation and evaluation of self-microemulsifying drug delivery system of carvedilol. Latin Am J Pharm. 2011;30:837–43.
23. [23]23. Grace XF, Krishnaraj K, Darsika C, Pushpalatha H, Chaudhari PS. A novel approach for topical gel containing smedds loaded with herbal drug. International Journal of Pharmaceutical Sciences and Research. 2018;9(3):1129–40.
24. [24]24. Bachhav YG, Patravale VB. Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation. Int J Pharma 2009;365(1-2):175–9.
25. [25]25. Shinde U, Pokharkar S, Modani S. Design and evaluation of microemulsion gel system of nadifloxacin. Indian J Pharma Sci 2012;74(3):237.
26. [26]26. Dalmora M, Dalmora S, Oliveira AGd. Inclusion complex of piroxicam with β-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharma 2001;222(1):45–55.
27. [27]27. Shishu, Rajan S, Kamalpreet. Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections. AAPS PharmSciTech. 2009;10(2):559–65.
28. [28]28. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Potentials and challenges in self-nanoemulsifying drug delivery systems. Expert opinion on drug delivery. 2012;9(10):1305–17.
29. [29]29. Midha K, Nagpa; M, Aggarwal G, Thakur GS. Development of dispersible self-microemulsifying tablet of atorvastatin. Pharmaceutical Methods. 2015;6(1):9–25.
30. [30]30. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Critical Reviews™ in Therapeutic Drug Carrier Systems. 1999;16(5).
31. [31]31. Carvalho FC, Barbi MS, Sarmento VHV, Chiavacci LA, Netto FM, Gremião MP. Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties. Journal of Pharmacy and Pharmacology. 2010;62(4):430–9.
32. [32]32. Bousmina M. Rheology of polymer blends: linear model for viscoelastic emulsions. Rheologica Acta. 1999;38(1):73–83.
33. [33]33. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen T, Urtti A. Microemulsions for topical delivery of estradiol. International Journal of Pharmaceutics. 2003;254(2):99–107.
34. [34]34. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Advanced drug delivery reviews. 2002;54:S77–S98.

Authors (2)